TrialEuropean journal of clinical pharmacology2016
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
Yanli Zhuang et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
33 papers cite it
this paperpooled ittrialcites it